In the BioHarmony Drug Report Database

"Preview" Icon

Lenvatinib

Lenvima, Kisplyx (lenvatinib) is a small molecule pharmaceutical. Lenvatinib was first approved as Lenvima on 2015-02-13. It is used to treat renal cell carcinoma and thyroid neoplasms in the USA. It has been approved in Europe to treat renal cell carcinoma and thyroid neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 2 and vascular endothelial growth factor receptor 3. Lenvima’s patents are valid until 2035-08-26 (FDA).

 

Trade Name

 

Kisplyx, Lenvima
 

Common Name

 

lenvatinib
 

ChEMBL ID

 

CHEMBL1289601
 

Indication

 

renal cell carcinoma, thyroid neoplasms
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Lenvatinib structure rendering